Cargando…

Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting

PURPOSE: To determine the exposure–response (ER) relationships between atezolizumab exposure and efficacy or safety in patients with advanced non-small cell lung cancer (NSCLC) or urothelial carcinoma (UC) and to identify alternative dosing regimens. METHODS: ER analyses were conducted using pooled...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morrissey, Kari M., Marchand, Mathilde, Patel, Hina, Zhang, Rong, Wu, Benjamin, Phyllis Chan, H., Mecke, Almut, Girish, Sandhya, Jin, Jin Y., Winter, Helen R., Bruno, René
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6820606/ https://www.ncbi.nlm.nih.gov/pubmed/31542806 http://dx.doi.org/10.1007/s00280-019-03954-8

Ejemplares similares

Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1)
por: Wu, Benjamin, et al.
Publicado: (2021)

Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer
por: Shemesh, Colby S., et al.
Publicado: (2019)

Prediction of overall survival in patients across solid tumors following atezolizumab treatments: A tumor growth inhibition–overall survival modeling framework
por: Chan, Phyllis, et al.
Publicado: (2021)

Impact of Dose Delays and Alternative Dosing Regimens on Pertuzumab Pharmacokinetics
por: Liu, Stephanie N., et al.
Publicado: (2021)

Value of postmarketing surveillance studies in achieving a complete picture of antimigraine agents: using almotriptan as an example
por: Pascual, J., et al.
Publicado: (2006)

The Importance of Registries in the Postmarketing Surveillance of Surgical Meshes
por: Köckerling, Ferdinand, et al.
Publicado: (2018)

Tumor Time‐Course Predicts Overall Survival in Non‐Small Cell Lung Cancer Patients Treated with Atezolizumab: Dependency on Follow‐Up Time
por: Netterberg, Ida, et al.
Publicado: (2020)

Sucrose-Formulated Recombinant Factor VIII Dosing Flexibility in Prophylaxis Regimens: Experience from Postmarketing Surveillance Studies
por: Humphries, Thomas J., et al.
Publicado: (2015)

Effectiveness of Additional Risk Minimization Measures for Atezolizumab in the European Union
por: Patel, Hina, et al.
Publicado: (2021)

Postmarketing pharmacovigilance: Remdesivir and cardiovascular events
por: Sullivan, John T.
Publicado: (2022)

Postmarketing Safety Study Tool: A Web Based, Dynamic, and Interoperable System for Postmarketing Drug Surveillance Studies
por: Sinaci, A. Anil, et al.
Publicado: (2015)

Results of a Dose‐Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non–Small Cell Lung Cancer
por: Felip, Enriqueta, et al.
Publicado: (2021)

Postmarketing Surveillance of Pregnancy Outcomes With Dolutegravir Use
por: Crawford, Melissa, et al.
Publicado: (2020)

EU postmarket surveillance plans for medical devices
por: Pane, Josep, et al.
Publicado: (2019)

Postmarketing Surveillance Study of the Efficacy and Safety of Phentermine in Patients with Obesity
por: Kim, Hyun Ok, et al.
Publicado: (2013)

External validation of a tumor growth inhibition-overall survival model in non-small-cell lung cancer based on atezolizumab studies using alectinib data
por: Kassir, Nastya, et al.
Publicado: (2023)

Atezolizumab plus platinum-based regimen and bevacizumab: is it time to consider immunotherapy in a concurrent approach for lung cancer?
por: Bianco, Andrea, et al.
Publicado: (2019)

Development of a pediatric physiologically-based pharmacokinetic model to support recommended dosing of atezolizumab in children with solid tumors
por: Huang, Weize, et al.
Publicado: (2022)

Improving the Postmarket Surveillance of Total Joint Arthroplasty Devices
por: Mahomed, Nizar N, et al.
Publicado: (2008)

Sleep-Walking with Zolpidem: Need for Continued Postmarketing Surveillance
por: Sharma, Ajitha, et al.
Publicado: (2015)

Descriptive analysis of postmarket surveillance data for hip implants
por: Pane, Josep, et al.
Publicado: (2020)

Postmarket Modifications of High-risk Plastic Surgery Devices
por: Olaiya, Oluwatobi R., et al.
Publicado: (2020)

Postmarketing Analysis of Misuse, Abuse, and Diversion of Xtampza ER
por: Geoffrey Severtson, Stevan, et al.
Publicado: (2020)

Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy
por: Day, John W., et al.
Publicado: (2021)

14. Postmarketing Safety Experience With MenACWY-TT
por: Serra, Lidia, et al.
Publicado: (2021)

Current development in medical devices postmarket surveillance in Taiwan
por: Lan, Cheng-Wen, et al.
Publicado: (2014)

Alternative tests: carcinogenesis as an example.
por: Schwetz, B, et al.
Publicado: (1998)

Population pharmacokinetics of bevacizumab in cancer patients with external validation
por: Han, Kelong, et al.
Publicado: (2016)

Phase Ib study of patients with metastatic castrate-resistant prostate cancer treated with different sequencing regimens of atezolizumab and sipuleucel-T
por: Dorff, Tanya, et al.
Publicado: (2021)

Pan‐cancer population pharmacokinetics and exposure‐safety and ‐efficacy analyses of atezolizumab in patients with high tumor mutational burden
por: Shemesh, Colby S., et al.
Publicado: (2020)

Atezolizumab Induces Necroptosis and Contributes to Hepatotoxicity of Human Hepatocytes
por: Endo, Yukinori, et al.
Publicado: (2023)

Postmarketing Safety Surveillance and Reevaluation of Danhong Injection: Clinical Study of 30888 Cases
por: Li, Xue-Lin, et al.
Publicado: (2015)

Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2)
por: Peters, Solange, et al.
Publicado: (2021)

Deriving meaningful insights from clinical trial and postmarketing safety data: Perspectives from India
por: Harugeri, Anand, et al.
Publicado: (2017)

Ten-Year Global Postmarket Safety Surveillance of Delayed Complications With a Flexible Cheek Filler
por: Cohen, Joel L., et al.
Publicado: (2022)

Atezolizumab plus bevacizumab and tremelimumab plus durvalumab: how should we choose these two immunotherapy regimens for advanced hepatocellular carcinoma?
por: Hatanaka, Takeshi, et al.
Publicado: (2022)

Development, Production, and Postmarketing Surveillance of Hepatitis A Vaccines in China
por: Cui, Fuqiang, et al.
Publicado: (2014)

Signal detection using change point analysis in postmarket surveillance(†)
por: Xu, Zhiheng, et al.
Publicado: (2015)

Safety analysis of Ziagen® (abacavir sulfate) in postmarketing surveillance in Japan†
por: Kurita, Tomoko, et al.
Publicado: (2014)

An Evaluation of “Drug Ineffective” Postmarketing Reports in Drug Safety Surveillance
por: Misu, Takashi, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_9o1h9cilpamh5051knd991uuh4